ESR2 and colorectal carcinoma: 17β-estradiol and progesterone monotherapies have the same anticancer effects and enhance the tumor-killing effects of CRC in men through the promotion of androgen deprivation mediated by ERβ and PGR, while also blocking oncogenic pathways regulated by ERα (68).